- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
The State of Biosimilars in the United States: The Center for Biosimilars® Peer Exchange
The introduction of biosimilars to the US market has led to an unprecedented amount of uncertainty as stakeholders try to understand the implications of their arrival. In the following Peer Exchange discussion from The Center for Biosimilars®, held in September 2017, industry experts discuss regulation, policy, and litigation issues in the world of biosimilars.
The introduction of biosimilars to the US market has led to an unprecedented amount of uncertainty as stakeholders try to understand the implications of their arrival. The Center for Biosimilars®, a sister site of The American Journal of Managed Care®, serves as an online resource that brings together the worlds of clinical, business, regulatory, policy, and economic outcomes of biosimilars.
The introduction of biosimilars to the United States provides great promise, as they are expected to bring down the price of medications, but also challenges. Biosimilars face stringent regulatory requirements, continued education of patients and physicians, and ongoing litigation issues.
In the following Peer Exchange discussion from The Center for Biosimilars®, held in September 2017, industry experts discuss regulation, policy, and litigation issues in the world of biosimilars. For more insight into the world of biosimilar therapies, visit centerforbiosimilars.com.
Listen below or through one of these podcast services:
iTunes: http://apple.co/2eYWTss
TuneIn: http://bit.ly/2gv7iwj
Stitcher: http://bit.ly/2gCqtFg
Biosimilar Aflibercept P041 as Effective, Safe as Originator in nAMD
October 30th 2024Biosimilar aflibercept (P041) demonstrated comparable safety and efficacy to the originator aflibercept (Eylea) in treating patients with retinal conditions like neovascular age-related macular degeneration (nAMD).
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
